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Although APP mutations associated with inherited forms of Alzheimer’s
disease (AD) are relatively rare, detailed studies of these mutations may
prove critical for gaining important insights into the mechanism(s) and
etiology of AD. Here, we present a detailed biophysical characterization
of the structural properties of protofibrils formed by the Arctic variant
(E22G) of amyloid-b protein (Ab40ARC) as well as the effect of Ab40WT on
the distribution of the protofibrillar species formed by Ab40ARC by charac-
terizing biologically relevant mixtures of both proteins that may mimic
the situation in the heterozygous patients. These studies revealed that the
Arctic mutation accelerates both Ab oligomerization and fibrillogenesis
in vitro. In addition, Ab40ARC was observed to affect both the morphology
and the size distribution of Ab protofibrils. Electron microscopy
examination of the protofibrils formed by Ab40ARC revealed several mor-
phologies, including: (1) relatively compact spherical particles roughly
4–5 nm in diameter; (2) annular pore-like protofibrils; (3) large spherical
particles 18–25 nm in diameter; and (4) short filaments with chain-like
morphology. Conversion of Ab40ARC protofibrils to fibrils occurred more
rapidly than protofibrils formed in mixed solutions of Ab40WT/Ab40ARC,
suggesting that co-incubation of Ab40ARC with Ab40WT leads to kinetic
stabilization of Ab40ARC protofibrils. An increase in the ratio of AbWT/
AbMUT(Arctic), therefore, may result in the accumulation of potential neuro-
toxic protofibrils and acceleration of disease progression in familial
Alzheimer’s disease mutation carriers.
q 2003 Elsevier Ltd. All rights reserved.
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Introduction
Alzheimer’s disease (AD) is a progressive neuro-
degenerative disease that is characterized by the
presence of extracellular amyloid plaques and
intraneuronal neurofibrillary tangles in the
brain.1 – 3 Biochemical analysis of amyloid plaques
revealed that a main constituent is fibrillar aggre-
gates of a 39–42 amino acid residue peptide
referred to as the amyloid-b protein (Ab).4 Several
lines of evidence point towards a central role for
the process of Ab fibril formation in the etiology
of AD. Transgenic animals overexpressing mutant
forms of its precursor, the amyloid precursor pro-
tein (APP), develop amyloid plaques comprising
fibrillar Ab.5 Several pathogenic AD mutations
have been shown to affect the processing of APP,
resulting in increased levels of Ab, in particular
0022-2836/$ - see front matter q 2003 Elsevier Ltd. All rights reserved.
Supplementary data associated with this article can be
found at doi: 10.1016/S0022-2836(03)00927-6
E-mail address of the corresponding author:
plansbury@rics.bwh.harvard.edu
Abbreviations used: AD, Alzheimer’s disease; Arc,
Arctic mutant (E22G); WT, wild-type; AU, analytical
ultracentrifugation; SVAU, sedimentation velocity
analytical ultracentrifugation; EM, electron microscopy;
STEM, scanning transmission electron microscopy; SEC,
size-exclusion chromatography; FAD, familial Alzheimer’s
disease; ThT, thioflavin T; TMV, tobacco mosaic virus.
doi:10.1016/S0022-2836(03)00927-6 J. Mol. Biol. (2003) 332, 795–808
the more amyloidogenic variant Ab42.6 These data
implicate the process of amyloid fibril formation
as the cause of disease progression and neuro-
degeneration in AD.
The molecular mechanism(s) by which fibrilliza-
tion may cause neurodegeneration in AD and the
nature of the toxic species remains controversial.7
In vitro studies have demonstrated clearly that Ab
fibril formation occurs via a complex multi-step
nucleated polymerization mechanism that involves
discrete soluble oligomeric intermediates termed
ADDLS8 or protofibrils, which disappear upon
fibril formation.9 –12 Several lines of evidence
suggest that Ab protofibrils are a pathogenic
species. First, there is a lack of a clear correlation
between the amount of fibrillar Ab deposits at
autopsy and AD severity,13 whereas a correlation
exists between soluble Ab levels in the brain and
early cognitive dysfunction.14,15 It is noteworthy
that in these studies the location of Ab (intra-
cellular versus extracellular), and its aggregation
state (monomer, oligomers, or fibrils) have not
been well characterized. Second, transgenic
animals that overproduce APP exhibit neuronal
and behavioral abnormalities before amyloid
plaques can be detected.16,17 Third, non-fibrillar,
oligomeric forms of Ab alter neuronal function
and/or cause cell death.8,18 –20 Fourth, in some
models, inhibiting fibril formation does not
attenuate Ab-associated toxicity towards cultured
neurons.21,22 Fifth, an autosomal dominant
mutation (APPE693G or Ab (E22G)) with a clinical
phenotype similar to that of idiopathic AD was
shown to decrease Ab production in vivo and
promote protofibril formation in vitro.23
Most APP mutations associated with early onset
familial Alzheimer’s disease (FAD) are thought to
accelerate AD by modulating the proteolytic pro-
cessing of APP, which can increase the total con-
centration of Ab in the plasma and cerebrospinal
fluid and/or produce an increase in the ratio
Ab42/Ab40.24,25 However, the Arctic APP mutation
(E693G) is an exception; it causes a reduction in
Ab40 and Ab42 levels in plasma.23 A reduction in
Ab42 was observed also in conditioned media
from cells transfected with APPE693G.
23 With all the
evidence mounting in support of the pathogenic
protofibril hypothesis,26 one possible explanation
for the toxicity of the Arctic mutation is that it pro-
motes the formation of toxic aggregates, possibly
protofibrils.23 This hypothesis is supported by the
increased propensity of the Arctic variant to form
protofibrils in vitro. Recently, we showed that
Ab40ARC seems to more rapidly form novel annular
and pore-like protofibrillar structures (“amyloid
pores”), that resemble those formed by bacterial
pore-forming toxins.27 Here, we present detailed
biophysical characterizations of protofibrils formed
by Ab40WT and the Arctic variant (Ab40ARC), as
well as the biologically relevant mixtures of the
two proteins that may model the situation in the
heterozygous patients.
Results
The Arctic mutation accelerates Ab40
fibrillogenesis in vitro
Under the conditions described here, Ab40ARC
forms fibrils more rapidly than Ab40WT. Three
different established protocols were used to pre-
pare Ab40 (the DMSO/water/Tris method, the
NaOH method18 and the NaCl/PO4 method;
23 see
Materials and Methods). Ab40WT, and Ab40ARC
(100 mM) were incubated at room temperature
without stirring, and fibril formation was moni-
tored by the thioflavin T (ThT) binding assay. ThT
Figure 1. The Arctic mutation accelerates Ab40 fibrillogenesis. A comparison of amyloid fibril formation (ThT
binding) of Ab40WT (broken lines) and Ab40ARC (continuous lines) revealed that the Arctic mutation accelerates Ab
fibrillization. (a) Three different protocols (DMSO/water/Tris method, blue; NaOH method, red; and NaCl/PO4
method, green) were employed to ensure that the aggregation was not dependent on the method of Ab monomer
preparation. Ab40WT and Ab40ARC (100 mM) were incubated at room temperature without stirring, and fibril formation
was monitored using the ThT binding assay. (b) A fourth method of preparation gave a similar result. In this exper-
iment, Ab40WT (shaded bars) and Ab40ARC (filled bars) monomers were isolated by SEC from a GdnHCl-treated
A40b stock solution. AbWT and AbARC (20 mM) were incubated at 37 8C without stirring, and fibril formation was
monitored using the ThT binding assay.
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is an amyloid specific dye that exhibits an
enhanced emission maximum at 482 nm (excited
at 450 nm) upon binding to amyloid fibrils.
Fibrillization studies were carried out at room
temperature, because the Arctic variant aggregates
very rapidly at 37 8C (one to three hours at
100 mM). Figure 1(a) shows that Ab40ARC showed
a gradual increase of the ThT signal during the
first 24 hours of incubation, whereas Ab40WT
showed no change in the ThT signal even after
48 hours of incubation (RT) at pH 7.4. The three
different protocols yielded similar kinetic profiles
for Ab40WT and Ab40ARC fibrillogenesis, all con-
sistent with an accelerated rate of fibrillization for
Ab40ARC relative to Ab40WT. To further confirm
this finding, we used a fourth preparation protocol;
lyophilized Ab40WT and Ab40ARC were denatured
in 6 M guanidine-HCl (pH 7.4) and loaded onto a
Superdex 75 SEC column, producing a single peak
corresponding to an unstructured Ab monomer
(as determined by gel-filtration and circular
dichroism, data not shown). Monomeric Ab40ARC
and Ab40WT were collected and subjected to con-
ditions that favor fibril formation (37 8C, pH 7.4)
at ,20 mM. Under these conditions, Ab40ARC
fibrillized much faster than Ab40WT (Figure 1(b)).
The Arctic mutation promotes the formation of
annular protofibrils
To probe the effect of the Arctic mutation on the
structural properties of Ab, in particular Ab proto-
fibrillar intermediates, we monitored the aggrega-
tion of AbWT and AbARC by electron microscopy
Figure 2. The Arctic mutation promotes the formation of annular protofibrils (amyloid pores). Electron micrograph
of negatively stained Ab40ARC (100 mM) after incubation at room temperature for (a) eight hours, (b) 14 hours and (c)
19 hours. The insets in (b) and (c) show chain-like protofibril (II), whereas (b) (III) and (b) (IV) show annular and glob-
ular spheres, respectively. (d) EM image of negatively stained Ab40WT (100 mM) after incubation at room temperature
for 19 hours. The inset demonstrates that annular protofibrils can be formed by Ab40WT, albeit much more slowly
and to a lesser extent than the Ab40ARC. Although amyloid fibril formation by Ab40ARC, but not by Ab40WT, was
observed during the first 19 hours of incubation, the EM images in this Figure were chosen to focus only on the
changes in the structural properties of protofibrillar Ab40ARC.
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(EM) as a function of time. Ab40WT and Ab40ARC
(100 mM) were incubated at room temperature and
aliquots were removed at regular intervals and
examined by EM. After eight hours, only AbARC
showed the formation of predominantly spherical
protofibrillar structures with an average diameter
of 4.5(^0.5) nm (Figure 2(a)). After 14 hours,
spheres (Figure 2(b), I), short chain-like protofibrils
(Figure 2(b), II) and annular protofibrils
(Figure 2(b), III) were observed for Ab40ARC. The
chain-like protofibrils appeared to be composed of
,5 nm spherical species (Figure 2(b), inset). Con-
sistent with earlier reports, the spheres represent
the assembly subunit of the chain-like
protofibrils.12,28,29 The annular protofibrils have an
outer diameter of 6–9 nm, and an inner diameter
of 1.5–2 nm. Large spherical species with an
average diameter of 18–24 nm were observed also
for Ab40ARC (Figure 2(b), IV). The amount of
spherical and annular protofibrils started to
diminish after 19 hours with short filaments and
fibrils (not shown in the selected images) emerging
as the predominant species, Figure 2(c). Although
amyloid fibril formation by Ab40ARC did occur
during the first 19 hours of incubation, the EM
images in Figure 2 were chosen to focus only on
the changes in the structural properties of proto-
fibrillar Ab40ARC. Ab40WT (100 mM) did not exhibit
significant protofibril formation over the incu-
bation period (at room temperature) of 14–
48 hours. However, after 19 hours some non-
fibrillar Ab40WT aggregates and some very rare
annular protofibrils could be detected by EM
(Figure 2(d)). These observations suggest that the
Ab40WT can form annular pore-like protofibrils,
but much more slowly and to a lesser extent than
Ab40ARC. Interestingly, after 19 hours the ThT
signal for the Ab40ARC solutions had reached a
plateau (Figure 1(a)), and the majority of the mono-
mer was consumed (suggesting complete conver-
sion of Ab40ARC to fibrils). However, EM showed
that a significant amount of Ab40ARC protofibrils
persisted along with amyloid fibrils. Complete
conversion of the remaining short chain-like proto-
fibrils to fibrils did occur with time (,72–
96 hours). Although we have focused on Ab40ARC,
preliminary studies with Ab42ARC showed annular
protofibrils forming more rapidly than Ab40ARC,
and annular protofibrils being the predominant
protofibrillar species after eight hours of
incubation at room temperature (Figure 3).
Co-incubation of the Arctic variant with Ab40WT
results in the kinetic stabilization of
Ab40ARC protofibrils
AD patients carrying the Arctic mutation are
heterozygotes and express both AbWT and AbARC.
However, the ratio of AbWT to AbARC (Ab ¼ Ab40 þ
Ab42) in Arctic carriers (equimolar in vivo pro-
duction cannot be assumed) and how it changes
with age have not been determined. To determine
whether changes in Ab40ARC/Ab40WT ratio have
an affect on Ab aggregation in vitro, we compared
the oligomerization and fibrillization properties of
each variant to mixed solutions. During a 70 hour
incubation at room temperature, the Ab40WT
(100 mM) sample did not show any significant pro-
tofibril formation (not shown) but a small and
Figure 3. Ab42ARC forms amyloid pores more rapidly
than Ab40ARC. Electron micrograph of negatively stained
Ab42ARC (100 mM) after incubation at room temperature
for (a) 30 minutes, (b) eight hours and (c) 19 hours.
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gradual increase in protofibril formation occurred
in the 200 mM Ab40WT solution (an in vitro model
of non-carriers “normal”) (Figure 4, black). In con-
trast, Ab40ARC ($100 mM) formed protofibril very
rapidly. The amount of accumulated Ab40ARC
oligomers remained constant during the first
24 hours (25 8C), but decreased significantly during
the next 46 hours (Figure 4, red). This is consistent
with the increase in the ThT signal observed at 55
and 70 hours, which coincide with a decrease in
the amount of Ab monomer in solution (see Figure
1 of the Supplementary Material). Interestingly,
addition of Ab40WT (50 or 100 mM) to Ab40ARC
(100 mM) (an in vitro model of heterzygous Arctic
carriers) resulted in the accumulation of oligomers,
which persisted in solution even after 62 hours of
incubation (Figure 4, blue and green). These results
demonstrate that Ab40ARC protofibrils (red bars)
moved along the assembly pathway more rapidly
(43 hours) than protofibrils formed in mixed sol-
utions (blue and green) of Ab40WT/Ab40ARC,
suggesting that addition of Ab40WT results in the
stabilization of Ab40ARC oligomers.
Fractionation of the protofibril peak results in
partial separation of distinct Ab40
protofibrillar morphologies
EM examination of the protofibrils formed by
the Arctic variant revealed several morphologies.
To facilitate further characterization of the different
protofibrillar species by high-resolution EM and
scanning transmission EM (STEM) methods, we
sought to partially purify these species by size-
exclusion chromatography (SEC) fractionation
using the stable protofibrils formed in an equi-
molar mixture of Ab40WT (100 mM) and Ab40ARC
(100 mM). After a 16 hour incubation at room tem-
perature, the mixture was spun at 13,000g, filtered
through a 0.2 mm pore size nylon spin filter (to
remove large aggregates) and then separated on a
Superose 6 gel-filtration column (4 8C). Ab40 proto-
fibrils were observed to be stable under these con-
ditions (4 8C, 20–30 hours). The oligomeric Ab40
eluted as broad peak between the void-volume
peak and the Ab40 monomer peak (Figure 5),
suggesting the presence of protofibrils of different
sizes and morphologies. The protofibrils were
divided into seven fractions, which were concen-
trated to 15–20 mM and characterized by EM. The
EM images (Figure 6) revealed that early fractions
(F1–F5, only F2, F4, and F5 are shown) contained
predominately short filaments, 4–5 nm wide and
50–100 nm long. Among the filaments were also
spherical and ring-shaped structures (,6–9 nm in
diameter). In contrast, very few filaments were evi-
dent in the late fraction (F7), which contained
numerous, ring-shaped structures. In addition, the
filaments in fractions F5–F7 were shorter than
those in the earlier fractions, suggesting that partial
separation of filaments of different sizes was
achieved by the Superose 6 column. Examination
of fraction F7 revealed that it contained a signifi-
cant amount of annular protofibrils in addition to
the spheres and large spherical oligomeric species.
We did observe some variation in protofibril stab-
ility between different preparations. In some cases,
a shift in the size distribution of the protofibrils
toward higher molecular mass protofibrillar
species was observed during the 16–24 hour pro-
cedure. Shortening both the incubation time for
inducing protofibril formation and the fraction-
ation time could minimize these changes. Partial
separation of the protofibrillar species was
possible; in particular, separation of the chain-like
protofibrils from the spheres and annular species.
Incubation (20–48 hours) of each of the purified
protofibril fractions at 37 8C resulted in their con-
version into amyloid fibrils (see Figure 2 of the
Supplementary Material), suggesting that they are
intermediates on the pathway or are in equilibrium
with on-pathway intermediates leading to Ab fibril
formation.
Single-particle averaging reveals a collection
of distinct protofibril species
Using a mixed equimolar solution of AbARC and
AbWT (100 mM each), we employed negative-stain
EM and single-particle averaging to analyze
fraction F7 (Figure 6) obtained by gel-filtration
(Superose 6) fractionation. A representative image
of fraction F7 is shown in Figure 7(a). A total of
5126 particles were selected from 25 images of
fraction F7. Multi-variate statistical analysis was
then used to divide the 5162 particles into 100 out-
put classes. These 100 classes fell into four major
groups; the structures are shown in Figure 7(b).
The first group consisted of annular structures
(amyloid pores) having an average diameter of
approximately 6–9 nm and a central stain-filled
cavity that is 1.5–2 nm in diameter (Figure 7(b)
Figure 4. Kinetic stabilization of Ab40ARC protofibrils
by Ab40WT. Protofibril formation during fibrillogenesis
was measured using the two Ab40 variants, Ab40ARC
and Ab40WT (100 mM), and relevant Ab40ARC/Ab40WT
mixtures. Red, 100 mM Ab40ARC; blue, 100 mM Ab40ARC/
50 mM Ab40WT; green, 100 mM Ab40ARC/100 mM
Ab40WT; black, 200 mM Ab40WT.
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1–3). These amyloid pores are similar to those
formed by a-synuclein and reminiscent of those
observed for bacterial pore-forming toxins.27,30,31
The second group showed rectangular particles
with a mean diameter of 5 nm and varying length
of 12–22 nm (Figure 7(b), 4–6). The third group
showed spherical aggregates with a mean diameter
of 5(^0.5) nm (Figure 7(b), 7). The fourth group
Figure 5. Fractionation of the protofibril peak. Partial separation of Ab40 protofibrillar species by fractionation of the
oligomeric peak on a Superose 6 GF column. Gel-filtration chromatogram illustrating how the Ab40 oligomeric peak,
which was obtained by incubating Ab40ARC and Ab40WT at equimolar concentration (100 mM) for 16 hours at room
temperature, was divided into seven fractions (F1–F7). The inset shows the amount of protofibrils and monomers
present after the 16 hour incubation (RT).
Figure 6. Fractionation of the protofibril peak results in separation of distinct Ab40 protofibrillar species EM images
of fractions F2, F4, F5, and F7 shown at two different magnifications. The scale bars represent 100 nm (top panel) and
50 nm (bottom panel).
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showed large spherical aggregates, which ranged
in diameter from 18 nm to 25 nm (Figure 7(b),
8 and 9). The first, third and fourth groups rep-
resent the majority of structures observed in F7.
Quantitative analysis of the molecular mass
distribution of Ab protofibrils by SVAU
To determine the effect of the Arctic mutation on
the size distribution of Ab protofibrils, we per-
formed sedimentation velocity experiments on
purified (separated from monomer) protofibrils of
Ab40WT, Ab40ARC, Ab42WT, and Ab42ARC. The
results, summarized in Table. 1, demonstrate that
the Arctic mutation changes the size distribution
of Ab protofibrils in favor of higher molecular
mass species, especially in the case of Ab42ARC. In
addition, protofibrils formed by Ab40ARC and
Ab42ARC were observed to undergo rapid
conversion towards higher-order protofibrils. For
example, sedimentation velocity analytical ultra-
centrifugation (SVAU) analysis of the total AbARC
protofibrils, which were obtained by incubating
AbARC (200 mM) for 16–18 hours at room tempera-
ture, revealed three populations with average
sedimentation coefficients of 8 S, 15 S and 21 S
(Figure 8(a)). Further incubation (three to seven
hours more) at room temperature resulted in a
shift of the sedimentation coefficient distribution
towards the 21 S protofibrillar species (Figure 8(b)).
In the case of Ab42ARC conversion into higher-
order protofibrils occurred in the analytical ultra-
centrifuge during sedimentation velocity experi-
ments. This rapid conversion, and the dynamic
equilibrium that exist between the different AbARC
protofibrillar species and fibrils precluded accurate
determination of their molecular mass by sedimen-
tation equilibrium, because 24–30 hours of
incubation under centrifugal force are required to
reach equilibrium.
Quantitative analysis of the molecular mass
distribution of Ab protofibrils by STEM
STEM can be used to determine the molecular
mass of individual particles, independent of their
shape or hydrodynamic properties. To estimate
the stoichiometric composition of the various Ab
protofibrillar structures (spheres, large spherical
structures, annular, and short filaments), the mass
distribution of fractions (F5, F6 and F7) rich in
these species were analyzed by STEM. Figure 9(a)
and (b) shows electron micrographs of unstained/
freeze-dried particles obtained from fraction F5
and F7, respectively. A significant number of short
filament-like protofibrils were observed in fraction
Figure 7. Single-particle averaging reveals a collection of distinct protofibril species. EM image and single-particle
averaging of protofibrils reveal pore-like, short filaments and sphere-like morphologies. (a) EM of negatively stained
protofibrils from fraction 7 of the Superose 6 GF purified oligomeric peak of an equimolar mixed solution of AbARC
and AbWT (100 mM), which was incubated for 24 hours at room temperature prior to separation. (b) A gallery of class
averages calculated from a total of 5162 particles. The size of each box corresponds to 50 nm.
Table 1. Summary of analytical ultracentrifugation experiments carried out with WT and the Arctic variant of Ab40
and Ab42
Peptide Major species Minor species Notes
AbWT 1– 40 14 S 32 S
AbARC 1 –40 15 S 8 S, 21 S 21 S becomes the major species with time at 20 8C.
AbWT 1– 42 20 S 29 S
AbARC 1 –42 90 S, 35 S 26 S The different species are in dynamic equilibrium
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F5, whereas spherical protofibrils dominated frac-
tion F7, consistent with the TEM data (Figure 6).
Protofibrils of various sizes could be distinguished
and selected automatically by using a set of models
of overlapping sizes in the PCMass program,
which located all isolated particles in each image.
The predominant particle shapes observed were:
(a) short filaments (F1–F6); (b) relatively amor-
phous round particles 13–25 nm in diameter
(F5–F7); and (c) relatively compact particles
roughly 5–8 nm in diameter (F7), occasionally
with a central low-density area. Unlike SVAU,
where it is difficult to directly assign a specific S
value to a particular morphology, in STEM analysis
an appropriate model based on the shape of the
particles can be chosen to select the particles of
each morphology, thus allowing us to estimate the
mass distribution of each protofibrillar morph-
ology. In this way, we grouped and analyzed the
mass distribution of the short filaments
(Figure 9(c)) and spherical species (Figure 9(d))
(spheres of various sizes were grouped together)
in the last three fractions (F5, F6 and F7). Global
analysis of the short filament-like protofibrils in
fractions F5, F6 and F7 (Figure 9(c)) revealed a
Gaussian molecular mass distribution with a
broad peak of particles ranging in mass from
350 kDa to 800 kDa (81–186 Ab monomers), with
a trailing shoulder at 800–1000 kDa. Analysis of
the spherical protofibrils, including annular and
large globular structures gave a size from 80–
400 kDa, corresponding to 18–93 monomers
(Figure 9(d)). The majority of the particles
exhibited mass ranging from 150 kDa to 250 kDa
(,32–59 monomers). In addition, STEM analysis
revealed two other populations with mass distri-
butions ranging from 295 kDa to 450 kDa and
680 kDa to 880 kDa (Figure 8(d)), with the latter
species corresponding to the largest spherical
aggregates (18–24 nm) observed by EM.
Discussion
The Arctic mutation promotes Ab
oligomerization and fibrillogenesis
Although APP mutations associated with
inherited forms of AD are relatively rare, detailed
studies of these mutations may prove critical for
gaining important insights into the mechanism
and etiology of AD.32 Several mutations (Flemish
(A21G), Italian (E22K), Arctic (E22G), Dutch
(E22Q) and Iowa (D23N)) that are located around
the central hydrophobic core of Ab accelerate Ab
oligomerization (E22Q,10 and E22G23) and fibrillo-
genesis (E22Q and D23N33). Interestingly, the
Flemish mutation was reported to decrease the
rate of Ab fibrillogenesis.34 The exact mechanism
by which these mutations contribute to the patho-
genesis of AD is unknown.
While the effect of Ab mutations on the structure
and morphology of Ab fibrils has been investi-
gated extensively, little is known about the effect
of these mutations on the quaternary structure
and morphology distribution of early prefibrillar
intermediates, the protofibrils. Our studies on the
fibrillogenesis of the Arctic variant demonstrate
that the Arctic mutation promotes Ab oligomeriza-
tion, consistent with data reported by Nilsberth
and co-workers.23 In addition, our data demon-
strate that the Arctic mutation accelerates the
Figure 8. SVAU demonstrates rapid conversion between the different Ab40ARC protofibrils. The distributions of
sedimentation coefficients obtained from experiments performed on purified Ab40ARC protofibrils. The sedimentation
profiles were analyzed using the time-derivative method to yield the apparent distribution of sedimentation coeffi-
cients, g(s p). The prominent maximum corresponds to the sedimentation coefficient of the major species in solution.
The black line reflects the best least-squares fit of the data (O) to a three (a) and two species model using a Gaussian
function.
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fibrillogenesis of Ab40. This latter conclusion is in
disagreement with data reported by Nilsberth and
co-workers,23 which suggest that this mutation
does not affect the rate of Ab40 fibrillogenesis.
The reasons for this disagreement may involve
details of experimental conditions. In our studies,
the kinetics of Ab fibril formation was monitored
by measuring directly the binding of the amyloid-
specific dye ThT to the Ab fibrils, whereas
Nilsberth et al. used a technique (SEC) that
measures the amount of fibril formation indirectly.
Interpretation of the results from the latter
approach is likely to be complicated by fibrils dis-
sociation and/or interaction with the column
matrix during the SEC experiments. Although the
mechanism by which this mutation leads to an
acceleration of Ab oligomerization and fibrillo-
genesis remains undefined, reduction of the charge
state has been proposed to lead to an enhanced
rate of oligomerization and/or amyloid fibril
formation by amyloid-forming proteins.35,36
The different Ab protofibrillar morphologies
seem to be related
Although previous studies have employed
SVAU to estimate the molecular size distribution
of protofibrils, the heterogeneity of the protofibril
preparations used precluded the assignment of
molecular mass averages to a particular protofibril
species. To address this problem, we characterized
our protofibril preparations using STEM, which
allows quantitative mass analysis on specific proto-
fibrillar morphologies and sizes. Time-dependent
EM studies indicate that the spherical protofibrils
(an average diameter of 4.5(^0.5) nm) represent
the smallest Ab protofibrils detectable by EM and
STEM. Mass measurements by STEM of the
Figure 9. STEM analysis reveals heterogeneous but discrete populations of Ab40 protofibrils. Quantitative STEM
analysis of Ab40 particles obtained from purified oligomeric fractions of a 1:1 molar ratio solution of Ab40ARC and
Ab40WT (100 mM). EMs of the unstained/freeze-dried particles of (a) fraction 5 (major species ¼ short filaments) and
(b) fraction 7 (major species ¼ spherical and annular structures) and recorded by STEM. Light regions represent
areas of high-mass density and dark regions represent areas of low mass density. Tobacco mosaic virus (TMV) was
included in each specimen as an internal standard. Histograms showing molecular mass measurements of the particles
from oligomeric fraction F5, F6 and F7 using two different models for (c) rectangular and (d) spherical species.
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fraction containing mainly spheres and annular
protofibrils (F7), revealed at least three major
populations (based on their size) of protofibrils
with average masses of 160 kDa, 300 kDa and
800 kDa. The smallest Ab oligomers (4.5 nm
spheres) had an average mass of ,80–100 kDa
(19–23 monomers). These results are consistent
with earlier reports suggesting that assembly
intermediates must contain a minimum of ca 23
Ab40 monomers.37 Although fraction F7 contained
significant amount of annular protofibrils, it was
very difficult to distinguish annular structures
from spheres in the unstained STEM images.
Based on EM and STEM, we propose that the
second protofibrillar population with a mass distri-
bution ranging from 150 kDa to 250 kDa (,32–59
monomers) corresponds to the amyloid pores. The
highest mass species (800 kDa) may correspond to
the large spherical (18–25 nm) particles observed
by EM. The short filaments with chain-like
morphology exhibited a wide mass distribution
(380–800 kDa), consistent with the observed vari-
ability in their length. Given that the 4–5 nm
spheres have an average mass of 80–100 kDa, one
could conclude that the smallest filament, which
has an average mass of 400 kDa, is composed of
,4–5 spherical protofibrillar intermediates. This
estimate is consistent with our EM data (Figure 2).
The 4–5 nm spherical protofibrils resemble the
spherical protofibrils first identified by AFM9 – 12
and neurotoxic oligomers referred to as ADDLs.8
These spheres appear to be the precursors for the
short filaments described above (see Figure 2(b),
II).9,12 Additional studies have reported operation-
ally soluble aggregates of Ab protofibrils with
diameters ranging from 8 nm to 18 nm and
molecular masses of 0.5 MDa and 1 MDa (based
on atomic force microscopy and SVAU
measurements).29,38
During our studies of Ab and a-synuclein (both
form spherical and annular protofibrils),27 we have
observed that spherical oligomers of both Ab and
a-synuclein seem to have the highest affinity for
the mica surface, whereas annular protofibrils
have the lowest affinity; very few could be
detected using enriched annular fractions (our
unpublished results). In contrast, most Ab proto-
fibrillar species appear to adsorb equally to carbon-
coated grids used for EM and STEM studies. These
findings underscore the importance of supple-
menting imaging data (AFM or EM) with data
from complementary techniques (SVAU and
STEM).
Kinetic stabilization of Ab40ARC protofibrils by
Ab40WT
Individuals with the Arctic form of early onset
familial AD are heterozygotes; presumably pro-
ducing both Ab40WT and Ab40ARC in their brains.
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The ratio of the different Ab peptides is likely to
play a key role in governing the rate of Ab oligo-
merization and/or fibrillization, and, possibly, dis-
ease progression. Therefore, we compared
fibrillogenesis of a mixture of Ab40WT and
Ab40ARC to the individual variants Ab40WT and
Ab40ARC (model of a homozygote, none of which
is known to exist). Under conditions where
Ab40WT does not produce oligomers or fibrils,
Ab40ARC forms both protofibrils and fibrils. The
Ab40ARC protofibrils formed in the absence of
Ab40WT converted to fibrils, but addition of
Ab40WT to Ab40ARC resulted in the stabilization
and accumulation of protofibrils with eventual
conversion to fibrils. The requirement for the rela-
tively high stoichiometry of Ab40WT (1:1) (addition
of 25 mM Ab40WT to 100 mM Ab40ARC failed to
stabilize protofibrils, data not shown) argues
against a simple model where Ab40WT monomers
retard and/or inhibit Ab40ARC assembly into
amyloid fibrils by capping the ends of Ab40ARC
protofibrils. These results suggest that Ab40WT and
Ab40ARC may interact at an early stage in the
aggregation process. Interaction between mono-
meric Ab40WT and monomeric and/or proto-
fibrillar Ab40ARC could interfere with the
conformational changes required for protofibril
elongation or interfere with protofibril assembly
into amyloid fibrils leading to stabilization of
Ab40ARC protofibrils, as has been proposed to
explain the inhibitory properties exhibited by
Ab40 against Ab42 fibril formation.39 Alternatively,
protofibrils formed by Ab40WT could interact with
Ab40ARC protofibrils in a way that interferes with
further Ab40ARC protofibrils self-assembly into
amyloid fibrils. A similar observation has been
made for a-synuclein, which is associated with
familial Parkinson’s disease. Human a-synuclein
inhibits amyloid fibril formation of the more amy-
loidogenic mouse a-synuclein.40 Further studies
are required to distinguish between the models
proposed above.
Annular, pore-like protofibrils may be
responsible for Ab permeabilizing or channel-
like activity, and possibly AD
While early oligomeric intermediates, proto-
fibrils, have been implicated as the toxic species in
several amyloid diseases including PD,28,30,41 – 43
HD,44 British familial dementia,45 systemic
amyloidosis and familial amyloid
polyneuropathy,46 – 48,8 – 10 the mechanism of proto-
fibril toxicity is not understood. Recently, we
reported that pathogenic mutations in Parkinson’s
(A53T and A30P) and Alzheimer’s disease (Arctic
mutation, E22G) promote the formation of a
distinct protofibrillar subtype that we refer to as
amyloid pores.27,30 The morphology and the size-
selective permeabilization of synthetic vesicles by
protofibril fractions containing the annular proto-
fibrils, suggest a pore-like pathogenic mechanism
that is reminiscent of bacterial toxins such as
a-hemolysin.49 Furthermore, several amyloid-
forming proteins that are associated with neuro-
degenerative diseases (Alzheimer’s disease,
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Huntington disease and prion disease) have been
demonstrated to form ion-permeable pores in
vitro, at concentrations that are toxic in cell cul-
tures. In addition, the tendency of amyloid pro-
teins (including Ab,27,50 islet amyloid peptide
amylin,51,52 polyglutamine repeats,53 serum
amyloid A,54 b2-microglobulin,55 prion proteins56,57
and a-synuclein30,58,59) to form ion-permeable
pores correlates with the presence of the pore-like
structures. Thus, membrane disruption via pore
formation may be a general mechanism of cyto-
toxicity for neurodegenerative diseases.7,60 – 62
In summary, our results suggest that an increase
in the ratio of AbWT/AbARC in FAD mutation car-
riers would favor the formation and accumulation
of stable protofibrillar intermediates of Ab, result-
ing in an enhancement of its neurotoxic properties
and accelerated disease progression. Although the
nature of the pathogenic species in vivo and its
mechanism of action remain controversial, our
studies suggest that amyloid pore formation and
membrane disruption may be linked to the patho-
genesis of AD. If this hypothesis is correct, then
drug-like molecules that inhibit pore formation
and/or membrane permeabilization could be
novel therapeutics against AD. Furthermore, the
identification of small molecules or mutations that
promote or inhibit amyloid pores should facilitate
mechanistic studies.
Materials and Methods
Peptides
Ab40WT and the Arctic variant Ab40ARC (E22G), were
purchased as TFA salts from the Biopolymer Facility at
Brigham and Women’s Hospital. All peptides were
dissolved using their true peptide weight.
Solubilization of Ab
The WT and Arctic (Arc) peptides were dissolved
individually using three different protocols to compare
their fibrillogenesis in different buffers: (1) in the
DMSO/water/Tris method peptides were dissolved in
100% DMSO then in water and Tris (pH 7.4). The final
concentrations of peptide, DMSO, and Tris were
100 mM, 5%, and 10 mM, respectively. (2) The NaOH
method,18 peptides were dissolved using the NaOH
method because of its ability to readily dissolve the pep-
tide, control the pH, and reduce the rate of aggregation
(see data below). Peptide was dissolved at 4.2 mg/ml in
1 mM NaOH containing phenol red, followed by empiri-
cally adding 130–150 ml of 10 mM NaOH to bring the
sample to pH 7.0–7.4 using the added phenol red as an
indicator. The sample was diluted with water and
10 £ PBS, bringing the final peptide concentration to
500 mM in PBS (pH 7.4). Samples were then diluted to
100 mM in water. (3) The NaCl/PO4 method;
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were dissolved in water to 100 mM, with sodium phos-
phate and NaCl at final concentrations of 50 mM and
100 mM respectively.
Ab40WT 1 Ab40ARC mixed incubations
Individual peptides were dissolved with NaOH and
PBS, as stated above, to give a concentration of 500 mM
peptide in PBS (pH 7.4). WT and Arc were combined
and diluted in water, giving a final concentration of
100 mM for each peptide.
Preparation and purification of Ab protofibrils
To prepare Ab protofibrils, lyophilized synthetic Ab
(WT, Arc, or equimolar mixture of WT and Arc) was dis-
solved using one of the methods outlined above to
obtain a total concentration of 100 mM. The peptide
solutions were incubated at room temperature for 16–
24 hours, before being centrifuged at 13,000g for five
minutes to remove any insoluble particle(s). The super-
natants were loaded onto either a Superdex 75 HR
(Amersham Pharmacia) GF column (used to separate
protofibrils from low molecular mass Ab species) equi-
librated with protein buffer (5 mM Tris–HCl (pH 7.4),
70 mM NaCl) or a Superose 6 HR column (used to frac-
tionate Ab protofibrils) equilibrated with protein buffer
(10 mM Tris–HCl (pH 7.4), 150 mM NaCl). The protein
was eluted at a flow-rate of 0.5 ml/minute and 0.5 ml
fractions were collected. Fractions corresponding to the
oligomeric peak were split into seven fractions (F1–F7)
and used for biophysical studies. Purified protofibril
fractions were stored at 4 8C. Samples for EM and SVAU
were prepared and used within one to ten hours unless
indicated otherwise.
Quantification of monomeric and oligomeric Ab
by gel-filtration
Samples of Ab (100 mM), WT, Arc or mixtures of WT
and Arc were incubated at room temperature. Aliquots
(50 ml) were removed from each sample at various times
and filtered through a 0.2 mm pore size nylon spin filter
(Costar) to remove any insoluble particle. The filtrate
was injected onto a Superdex 200 HR column
(10 mm £ 30 mm) equilibrated with protein buffer
(10 mM Tris–HCl (pH 7.4), 150 mM NaCl). The relative
amount of protofibrils and LMW Ab were quantified by
calculating the area under the peak corresponding to
each species using the Millenium Software (Waters,
Milford, MA).
Thioflavin T assay for fibril formation
Fluorescence measurements of 5 ml of 100 mM Ab
solution in 10 ml of 100 mM ThT þ 85 ml of 90 mM
glycine–NaOH (pH 8.5 at 25 8C) (Ex ¼ 450 nm,
Em ¼ 482 nm) as described.41
Electron microscopy and image processing
Purified protofibrillar fractions of Ab were diluted
twofold with protein buffer (10 mM Tris–HCl (pH 7.4),
150 mM NaCl) prior to adsorption to glow-discharged,
carbon-coated copper grids. Grids were washed with
four drops of buffer and stained with two drops of
freshly prepared 0.75% (w/v) uranyl formate (Pfaltz &
Bauer, Waterbury, CT 06708). Specimens were inspected
with a Philips Tecnai 12 electron microscope operated at
120 kV and images were taken at a nominal magnifi-
cation of 52,000 £ using low-dose procedures. For
image processing, 25 images of Ab were digitized with
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a Zeiss SCAI scanner using a pixel size of 4.04 A˚ at the
specimen level. From the digitized images, 5162 particles
were selected for further computational processing using
the SPIDER image processing package.63 The 5162 par-
ticle images were subjected to ten rounds of alignment
and classification specifying 100 output classes.
Sedimentation velocity analytical
ultracentrifugation (SVAU)
Sedimentation velocity data were collected in a tem-
perature-controlled Beckman XL-A. A double-sector
cell, equipped with a 12 mm Epon centerpiece and
quartz windows was loaded with 400–420 ml of protein
sample. Data were collected at rotor speeds of 3000–
60,000 rpm in continuous mode at 25 8C, with a step
size of 0.005 cm and an average of three scans per point.
Purified void fractions isolated by gel-filtration and
stored at 4 8C were incubated at room temperature for
one to two hours prior to the SVAU experiments at
25 8C. The sedimentation velocity data were analyzed as
described.30
Scanning transmission electron microscopy (STEM)
Protofibrillar fractions of Ab were analyzed by STEM
at the Brookhaven National Laboratory using 3–10 ml of
the protein samples, as described.30 Protein samples
were applied to a thin carbon film supported by a thick
holey film on titanium grids, washed extensively, wicked
to a thin layer, frozen rapidly to avoid formation of ice
crystals, and freeze-dried overnight. The freeze-dried,
unstained specimens were transferred to the STEM
under vacuum and examined at 2150 8C and 40 kV
using the annular dark-field detector mode. Tobacco
mosaic virus (TMV) was included in all specimens to
monitor preparation quality. Digital images of 512 £ 512
pixels with 1 nm spacing were recorded at an average
dose of 300–1000 enm22. The STEM data were analyzed
as described, using the PCMass program.64
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